EP Antagonist-Elicited Extracellular Vesicles from Mesenchymal Stem Cells Rescue Cognition/Learning Deficiencies by Restoring Brain Cellular Functions
Overview
Pharmacology
Authors
Affiliations
Adult brains have limited regenerative capacity. Consequently, both brain damage and neurodegenerative diseases often cause functional impairment for patients. Mesenchymal stem cells (MSCs), one type of adult stem cells, can be isolated from various adult tissues. MSCs have been used in clinical trials to treat human diseases and the therapeutic potentials of the MSC-derived secretome and extracellular vesicles (EVs) have been under investigation. We found that blocking the prostaglandin E /prostaglandin E receptor 4 (PGE /EP ) signaling pathway in MSCs with EP antagonists increased EV release and promoted the sorting of specific proteins, including anti-inflammatory cytokines and factors that modify astrocyte function, blood-brain barrier integrity, and microglial migration into the damaged hippocampus, into the EVs. Systemic administration of EP antagonist-elicited MSC EVs repaired deficiencies of cognition, learning and memory, inhibited reactive astrogliosis, attenuated extensive inflammation, reduced microglial infiltration into the damaged hippocampus, and increased blood-brain barrier integrity when administered to mice following hippocampal damage. Stem Cells Translational Medicine 2019.
Mincheva G, Moreno-Manzano V, Felipo V, Llansola M Stem Cell Res Ther. 2024; 15(1):472.
PMID: 39696620 PMC: 11656658. DOI: 10.1186/s13287-024-04076-6.
Composition, functions, and applications of exosomal membrane proteins.
Xu F, Luo S, Lu P, Cai C, Li W, Li C Front Immunol. 2024; 15:1408415.
PMID: 39148736 PMC: 11324478. DOI: 10.3389/fimmu.2024.1408415.
Unraveling the Emerging Niche Role of Extracellular Vesicles (EVs) in Traumatic Brain Injury (TBI).
Ashique S, Pal R, Sharma H, Mishra N, Garg A CNS Neurol Disord Drug Targets. 2024; 23(11):1357-1370.
PMID: 38351688 DOI: 10.2174/0118715273288155240201065041.
Exosomes: potential targets for the diagnosis and treatment of neuropsychiatric disorders.
Li H, Yuan Y, Xie Q, Dong Z J Transl Med. 2024; 22(1):115.
PMID: 38287384 PMC: 10826005. DOI: 10.1186/s12967-024-04893-6.
Xu H, Li H, Zhang P, Gao Y, Ma H, Gao T Neural Regen Res. 2024; 19(9):1947-1953.
PMID: 38227520 PMC: 11040311. DOI: 10.4103/1673-5374.390961.